Thomas Jouary

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Pharmacology +7

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

Georgina V. Long, Keith T. Flaherty, Daniil Stroyakovskiy et al. · Annals of Oncology · 2017 · 652 citations · Full text

Medicine, Oncology, Pharmacology +17

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers et al. · The Lancet Oncology · 2018 · 198 citations · Full text

Medicine, Immunology, Oncology +14

Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study

Thomas Jouary, C. Leyral, Brigitte Dréno et al. · Annals of Oncology · 2011 · 191 citations · Full text

Medicine, Oncology, Surgery +10